Don Frail
InvestorSenior Advisor at Frazier Life Sciences · Senior Advisor at Frazier Healthcare Partners
United States
About
Don Frail is founder and CEO of Alceptor Therapeutics and has held senior leadership positions in drug discovery and clinical development across multiple therapeutic areas. He has built and managed R&D organizations ranging from 25 to 200 employees, with experience advancing more than 25 compounds into clinical development across modalities including small molecules, monoclonal antibodies, gene therapy, and CRISPR. Since 2015, Frail has participated in more than 25 business development transactions, including acquisitions, licensing agreements, and partnership structures.
Experience
- Alceptor TherapeuticsFounder, CEO, Board Membercurrent2020 — presentSouthern California
- Frazier Healthcare PartnersSenior Advisorcurrent2020 — presentSouthern California
- Iolyx TherapeuticsBoard Membercurrent2021 — presentSan Francisco Bay Area
- Ventyx BiosciencesScientific Advisory Board2024 — 2026
- Escient PharmaceuticalsScientific Advisory Board2022 — 2024San Diego, CA
- Pandion TherapeuticsBoard Member2019 — 2021Cambridge, Massachusetts, United States
- AllerganSenior Vice President, Research, External Science & Innovation, Non-Clinical/Translational Sciences2014 — 2020Irvine, CA
- AstraZenecaVice President, Science, New Opportunities iMed/Emerging Innovations Unit2011 — 2014Greater Boston
- PfizerVice President, Pfizer Global Research and Development2007 — 2011St Louis, Missouri, United States
- PfizerVice President, Biology, Saint Louis Discovery2003 — 2007St Louis, Missouri, United States
- Pharmacia CorporationVice President, CNS Discovery2001 — 2003Kalamazoo, Michigan, United States
- WyethDirector, Women's Health1994 — 2001Radnor, Pennsylvania, United States
Skills & more
Drug DiscoveryDrug DevelopmentClinical DevelopmentTherapeutic AreasClinical TrialsClinical ResearchEndocrinologyMedicineBiomarker DiscoveryNeurosciencePharmacologyOncology
+12 more
ScienceBiotechnologyLaboratoryR&DBiochemistryTranslational MedicineBiopharmaceuticalsImmunologyCROPharmaceutical IndustryLifesciencesLife SciencesFrom Don's professional profile.
Colleagues at Frazier Life Sciences
Adam Simpson
Venture Partner at Frazier Life Sciences
Aditya Kohli
Partner at Frazier Life Sciences
Albert Cha
Managing Partner at Frazier Life Sciences
Ali Jackson
Vice President and Counsel, Public Funds at Frazier Life Sciences
Amanda Wilson
Senior Tax Manager at Frazier Life Sciences
Angel Martin
Senior Associate at Frazier Life Sciences
Angie You
Senior Advisor at Frazier Life Sciences
Anna H. Chen
Partner at Frazier Life Sciences
Frequently asked questions
- Who is Don Frail?
- Don Frail is founder and CEO of Alceptor Therapeutics and has held senior leadership positions in drug discovery and clinical development across multiple therapeutic areas. He has built and managed R&D organizations ranging from 25 to 200 employees, with experience advancing more than 25 compounds into clinical development across modalities including small molecules, monoclonal antibodies, gene therapy, and CRISPR. Since 2015, Frail has participated in more than 25 business development transactions, including acquisitions, licensing agreements, and partnership structures.
- Where does Don Frail work?
- Don Frail is Senior Advisor at Frazier Life Sciences.
- Where did Don Frail go to school?
- Don Frail studied at Washington University School of Medicine in St. Louis (Post Doctoral Fellow); McGill University (Doctor of Philosophy (Ph.D.)); Stony Brook University (Bachelor of Science - BS, Biology and Mathematics).
Same school
Also attended Washington University School of Medicine in St. Louis15
Reid HuberPartner at Third Rock VenturesDavid CohnInterim Chief Executive Officer and Chief Medical Officer at Oncology VenturesGlenn PierceScientific Advisory Group Co-Chair at Pathway to CuresDani TaoMarketing Coordinator at Untapped VenturesBen ScruggsPartner at Hatteras Venture PartnersDave VreelandSenior Managing Partner at Caduceus Capital Partners
+ 9 more
Also attended McGill University571
Harley FinkelsteinInvestor at Felicis VenturesMattias LjungmanInvestor at Moonfire VenturesNoubar AfeyanInvestor at Flagship PioneeringDavid NaultGeneral Partner at Luge CapitalLaviva MazharPrincipal at Luge CapitalLisa PurcellInvestor at Third Rock Ventures
+ 565 more
Also attended Stony Brook University66
Mojca SkoberneEntrepreneur in Residence at GV (Google Ventures)Alex BardManaging Director at Redpoint VenturesKonstantinos AprilakisPartner at Deerfield Management CompanyDavid WhittakerVenture Partner at Elm Street VenturesJeffrey SachsAdvisor at Windham Capital PartnersDalia ElMohamadyCFO at Sawari Ventures
+ 60 more
Shared employers
Also worked at Ventyx Biosciences3
Also worked at Allergan29
Jim CaggianoChief Executive Officer, Evolve Biologics at Two Bear CapitalSean AinsworthBiotech CEO at FemHealth VenturesEhsan SadriInvestor at Visionary VenturesIrina MiettinenHead of Finance at Maki.vcSam AckermanAssistant Controller at Declaration PartnersKevin McAdamsSenior Analyst at Declaration Partners
+ 23 more
Also worked at AstraZeneca70
Detlev BiniszkiewiczManaging Director at MPM BioImpactBriggs MorrisonEntrepreneur Partner at MPM BioImpactJung Lee, PhDVenture Partner at Adelphi Ventures Management, LlcJohan LundVenture Partner at ScietyIliam BarkinoInvestor at IndustrifondenSara JawadInvestor at Industrifonden
+ 64 more
Also worked at Pfizer188
Jigar RaythathaInvestor at Third Rock VenturesAbbie CelnikerInvestor at Third Rock VenturesErin MooreInvestor at Third Rock VenturesJeb KeiperInvestor at Third Rock VenturesRichard ChesworthInvestor at Third Rock VenturesSamar JahanVice President of Finance at Mission Biocapital
+ 182 more